Aligos Therapeutics Inc (ALGS) - News Archive

Aligos Therapeutics Sets Stage for EASL Congress 2025 with Eight Accepted s SOUTH SAN FRANCISCO, Calif. April 23, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to en...

Aligos Therapeutics Moves Forward with Strategic Inducement Grants to Attract TalentSOUTH SAN FRANCISCO, Calif. Aligos Therapeutics, Inc. (Nasdaq: ALGS), a promising player in the clinical-stage biopharmaceutical sector...

SOUTH SAN FRANCISCO, Calif. In a clear sign of its ongoing strategic growth and commitment to attracting top talent, Aligos Therapeutics, Inc. (Nasdaq: ALGS) recently announced the grant of a non-qualified stock option...

Aligos Therapeutics Advances Hepatic Therapeutics with Landmark Discoveries in 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical organization pioneering the landscape of liver and viral d...

Aligos Therapeutics Expands Talent Pool with Strategic Stock Options Amid MASH Treatment Innovations By , Contributor SOUTH SAN FRANCISCO, Calif. Oct. 11, 2024 In a bold move signaling its commitment to fostering innova...

In a significant strategic move reflecting its commitment to advancing therapeutic interventions for liver diseases, Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company based in South Sa...

Aligos Therapeutics Reveals Positive Phase 2a HERALD Study Findings for ALG-055009 in MASH Treatment SOUTH SAN FRANCISCO, Calif. Sept. 19, 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a pioneering clinical stage bioph...

Aligos Therapeutics Rewards New Talent with Stock Inducement Grant: Future Impact on Share ValueSOUTH SAN FRANCISCO, Calif. Sept. 13, 2024 - In a bid to attract and retain top-tier talent, Aligos Therapeutics, Inc. (Nas...

Aligos Therapeutics Announces Reverse Stock Split: What It Means for InvestorsIn a recent press release, Aligos Therapeutics, a biopharmaceutical company focused on liver and viral diseases, announced a 1-for-25 reverse...

Aligos Therapeutics, a renowned clinical-stage biopharmaceutical company, has recently made significant progress in developing innovative therapeutics to combat chronic hepatitis B (CHB) and metabolic dysfunction-associ...

Positive Data Presented by Aligos Therapeutics at EASL Congress 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for liver and viral...

The pharmaceutical industry recently mourned the loss of Dr. Stephen A. Harrison, a renowned industry leader in metabolic dysfunction-associated steatohepatitis (MASH) research. With his profound expertise and guidance,...

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by the presence of fat, inflammation, and liver cell damage in individuals with metabolic dysfunction, such as obesity...

Aligos Therapeutics, a leading biopharmaceutical company, recently presented groundbreaking clinical data at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, held in Kyot...

Aligos Therapeutics, a prominent clinical stage biopharmaceutical company, has recently announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatit...

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data on Emerging HBV TherapiesNovember 16 Event to feature KOL perspective on Emerging HBV TherapiesIn the ever-evolving landscape...